Application of PDE5 inhibitor in preparation of drugs for reducing uric acid and protecting kidney

By preparing a sustained-release formulation using an ultra-low dose of PDE5 inhibitor and a soybean globulin-tannic acid-zinc ion complex carrier, the problem of excessively high dosage of existing PDE5 inhibitors is solved. This achieves the dual effects of significantly lowering uric acid and protecting the kidneys, reducing side effects and improving the safety and convenience of medication.

CN122376753APending Publication Date: 2026-07-14SHANDONG KAIPU FITE BIOTECHNOLOGY CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202610826658.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-06-10
Filing Date
2026-06-09
Publication Date
2026-07-14

AI Technical Summary

Technical Problem

Existing PDE5 inhibitors have excessively high dosages for lowering uric acid and protecting the kidneys, far exceeding the human safety threshold, and have side effects, making them ineffective in treating hyperuricemia and kidney disease.

Method used

Sustained-release or controlled-release formulations were prepared by combining ultra-low doses of PDE5 inhibitors (tadalafil, sildenafil, vandenafil, pyrazolopyrimidinone derivatives) with a soybean globulin-tannic acid-zinc ion complex carrier for lowering uric acid and protecting the kidneys, with a dosage range of 0.000125-0.0125 mg/kg.

Benefits of technology

It significantly reduces uric acid levels, repairs kidney damage caused by high uric acid, reduces drug toxicity and side effects, achieves long-lasting and stable drug efficacy, and improves medication safety and convenience.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and particularly discloses application of a PDE5 inhibitor in preparation of medicines for reducing uric acid and protecting kidneys. The research shows that the uric acid reduction mouse experiment of EGCG and the in-vitro PDE5 inhibition activity speculate the use dosage of the PDE5 specific inhibitor for uric acid reduction and / or kidney protection through concentration analogy, so that the concentration of the PDE5 inhibitor such as tadalafil is set to be 0.001-0.1 mg / kg, and the PDE5 inhibitor can be used for inhibiting kidney protection. Animal experiments find that tadalafil under the dosage has a remarkable uric acid reducing effect and a remarkable kidney protection function, the dosage of tadalafil applied to human bodies (adults with the weight of 60 kg) is 0.0075 mg to 0.75 mg every day, and the dosage range is far lower than the recommended dosage of drugs for treating ED and far lower than the use dosage of existing inventions. According to the invention, a new indication range of the ED medicine is increased, and the ED medicine can be expected to be quickly used clinically.
Need to check novelty before this filing date? Find Prior Art